Treating Children's Asthma Quickly Shortens Hospital Stay

Eileen Oldfield, Associate Editor
Published Online: Monday, April 23, 2012
Follow Pharmacy_Times:
Children given corticosteroids for asthma attacks soon after arriving at an emergency room have lower hospital admission rates and shorter treatment lengths.

In children with moderate to severe asthma, administering corticosteroids within 75 minutes of arrival at the emergency department (ED) decreases both hospital admission rates and length of treatment, according to the results of a study published online March 12, 2012, in Annals of Emergency Medicine.
 
Over a 12-week study period, researchers reviewed the charts of 1539 children seen for asthma attacks in the ED at Montreal Children’s Hospital of McGill University. Of these, they selected 406 study participants, all of whom were between 2 and 17 years of age, had moderate to severe respiratory obstruction, and had been treated with at least 1 dose of albuterol in the ED.
 
Of the 406 patients in the study, 88% had moderate asthma and 12% had severe asthma. Systemic corticosteroids were administered to 205 participants within 75 minutes of their initial ED assessment. Of the remaining 201 patients, 133 received corticosteroids after the 75-minute cut-off, and 68 did not receive corticosteroids at all.
 
The researchers determined that early administration of the corticosteroids significantly decreased rates of admission and treatment length. For each additional 30-minute delay in corticosteroid administration, a patient’s odds of being admitted to the hospital increased 1.23% and their duration of treatment increased by 60 minutes.
 
The researchers note that corticosteroid administration was more likely to be delayed for patients determined to be a lower triage priority. Likewise, patients with more severe respiratory obstruction were more likely to have the corticosteroids administered within the 75-minute window.
 
The study authors acknowledge that these typical treatment biases may have distorted their data, but note that it would be unethical to run a study in which treatment with corticosteroids was completely randomized. They also note that the bias was partially addressed by excluding cases of mild asthma and adjusting for attack severity.
 
To read the study, click here. (Registration required to access full text.)

Related Articles
Clinical guidelines and government agencies are increasingly encouraging clinicians to consider patients’ treatment preferences when chronic disease is present.
AstraZeneca and Abbott are teaming up to develop companion diagnostic blood tests that will identify patients with severe asthma who would benefit most from biological tralokinumab therapy.
Asthma controller medications are underused in neighborhoods with high rates of asthma-related emergency room use and hospitalization, but pharmacists are in a prime position to correct it.
The FDA today expanded the indication of fluticasone furoate/vilanterol (Breo Ellipta) for the treatment of asthma.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$